On Friday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE.
Neurona Therapeutics’ Post
More Relevant Posts
-
Yesterday, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here: https://lnkd.in/gXJvqA-s
-
-
Today, Neurona Therapeutics shared a positive clinical update from its NRTX-1001 Cell Therapy Trial in Drug-resistant Epilepsy at AES 2024 including SAFETY, LOW DOSE COHORT, HIGH DOSE COHORT, DURABILITY and COGNITION AND QUALITY OF LIFE. The full press release can be found here: https://lnkd.in/gXJvqA-s
-
-
⏰ Save The Date - 27th June ⏰ Join our upcoming webinar featuring a panel discussion on methods of streamlining the CAR-T workflow. As CAR-T cell therapy continues to advance it's important to address the challenges that come with it. One key issue is the manufacturing process, which can be costly and time-consuming. That's why efforts to create a more efficient CAR-T cell therapy manufacturing process are crucial. Join this webinar to learn more about the analytical tools that are contributing to these advancements! #celltherapy #CART
Discover how to engineer and analyze CAR-T cell signaling and activation using cutting-edge tools in our upcoming webinar. Learn from experts about innovative non-viral editing and analytical platforms that enhance CAR-T cell therapy efficiency. #CARTTherapy #GeneEditing #CancerResearch https://lnkd.in/gaQq5EVi
-
-
💡 New Developments in #Lupus Treatment At #ACR24, researchers shared preliminary findings on natural killer (NK) cell therapy, a potential “off-the-shelf” option for relapsed and refractory systemic #lupus erythematosus (#SLE). This innovative approach could offer new possibilities for patients living with lupus. 🔗Read more in an article by MedCentral, which features insights from Dr. Roberto Caricchio, FACR, who serves as Chair of the #LupusTherapeutics Lupus Clinical Investigators Network (LuCIN) Cell Therapy Advisory Group: https://lnkd.in/gBXGjT5b
-
-
Knowledge at the tip of your fingers: From selecting the right sites to optimizing study retention, here are the key steps in executing a cell therapy #clinicaltrial – get your guide to logistics here: https://bit.ly/43bWJTs #CellTherapy #ClinicalResearch #Logistics
-
Chief Medical Officer @ Nexus Alliance Biopharmaceuticals | Doctor of Medicine - MD
Current Indications and Challenges for CAR-T Therapy in Earlier Lines CAR-T cell therapy, initially reserved for last-line treatment, is now being explored and approved for earlier lines of therapy in various hematologic malignancies.
-
Discover how to engineer and analyze CAR-T cell signaling and activation using cutting-edge tools in our upcoming webinar. Learn from experts about innovative non-viral editing and analytical platforms that enhance CAR-T cell therapy efficiency. #CARTTherapy #GeneEditing #CancerResearch https://lnkd.in/gaQq5EVi
-
-
Helping researchers obtain faster, more sensitive and accurate Immunoassay results at Bio-Techne
🔍 Join our upcoming webinar to explore the latest advancements in CAR-T cell signaling and activation. Gain insights from leading experts on innovative non-viral editing 🧬 and analytical platforms that are revolutionizing the efficiency of CAR-T cell therapy. 🌟
Discover how to engineer and analyze CAR-T cell signaling and activation using cutting-edge tools in our upcoming webinar. Learn from experts about innovative non-viral editing and analytical platforms that enhance CAR-T cell therapy efficiency. #CARTTherapy #GeneEditing #CancerResearch https://lnkd.in/gaQq5EVi
-
Medical Doctor Seeking Opportunities in Biotechnology and Pharmaceutical Industry/ #Neuroscience #Neurology #Child Neurology #Rare Diseases #Oncology #Family Medicine
3wExciting news from Neurona Therapeutics! Advancing treatment options for drug-resistant epilepsy is truly groundbreaking. The focus on cognition and quality of life highlights the patient-centered approach we need in neurology. I’m inspired by this work and see incredible opportunities for collaboration and innovation in this space. Congratulations to the team for this milestone!